Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 152 Published: April 29, 2022 Report Code: GMDGDHC22145IDB

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure.

The Leiomyosarcoma – drugs in development research report provides a comprehensive overview on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.

Key Targets in the Leiomyosarcoma Pipeline Drugs Market

In the Leiomyosarcoma pipeline drugs market the key targets are Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Exportin 1, Fibroblast Growth Factor Receptor, Leukocyte Surface Antigen CD47, Platelet Derived Growth Factor Receptor Beta. Vascular Endothelial Growth Factor Receptor 2 has the highest number of pipeline products.

Leiomyosarcoma Pipeline Drugs Market, by Targets

Leiomyosarcoma Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Leiomyosarcoma Pipeline Drugs Market

Vascular Endothelial Growth Factor Receptor 2 Inhibitor has the highest number of pipeline products followed by Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing Latent Membrane Protein 1 , Cytotoxic To Cells Expressing Latent Membrane, Protein 2, Exportin 1 Inhibitor, and Fibroblast Growth Factor Receptor Inhibitor.

Leiomyosarcoma Pipeline Drugs Market, by MoA

Leiomyosarcoma Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Leiomyosarcoma Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Leiomyosarcoma pipeline drugs market are Intravenous, Oral, Subcutaneous, Intratumor, Intravenous Drip, Intravesical, Parenteral, Topical, Intradermal, and Intralesional. Intravenous has the maximum number of pipeline products.

Leiomyosarcoma Pipeline Drugs Market Analysis, by RoA

Leiomyosarcoma Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Leiomyosarcoma Pipeline Drugs Market

In the Leiomyosarcoma pipeline drugs market the key molecule types are Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Biologic, Gene-Modified Cell Therapy, Inactivated Vaccine, Monoclonal Antibody Conjugated, and Recombinant Peptide.

Leiomyosarcoma Pipeline Drugs Market, by Molecule Types

Leiomyosarcoma Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Leiomyosarcoma Pipeline Drugs Market

The major companies in the Leiomyosarcoma pipeline drugs market are Advenchen Laboratories LLC, AstraZeneca Plc, Pharma Mar SA, Karyopharm Therapeutics Inc, Merck KGaA, Pfizer Inc, 3SBio Inc, Actuate Therapeutics Inc, Agenus Inc, Alphamab Oncology, ALX Oncology Holdings Inc, Apexigen Inc, and APIM Therapeutics AS.

Leiomyosarcoma Pipeline Drugs Market, by Major Companies

Leiomyosarcoma Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Leiomyosarcoma Pipeline Drugs Market Overview

Key Targets Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Exportin 1, Fibroblast Growth Factor Receptor, Leukocyte Surface Antigen CD47, Platelet Derived Growth Factor Receptor Beta
Key Mechanisms of action Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing Latent Membrane Protein 1 , Cytotoxic To Cells Expressing Latent Membrane, Protein 2, Exportin 1 Inhibitor, and Fibroblast Growth Factor Receptor Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intratumor, Intravenous Drip, Intravesical, Parenteral, Topical, Intradermal, and Intralesional
Key molecule types Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Biologic, Gene-Modified Cell Therapy, Inactivated Vaccine, Monoclonal Antibody Conjugated, and Recombinant Peptide
Major companies Advenchen Laboratories LLC, AstraZeneca Plc, Pharma Mar SA, Karyopharm Therapeutics Inc, Merck KGaA, Pfizer Inc, 3SBio Inc, Actuate Therapeutics Inc, Agenus Inc, Alphamab Oncology, ALX Oncology Holdings Inc, Apexigen Inc, and APIM Therapeutics AS

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
  • The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leiomyosarcoma therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leiomyosarcoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • 3SBio Inc

    Actuate Therapeutics Inc

    Advenchen Laboratories LLC

    Agenus Inc

    Alphamab Oncology

    ALX Oncology Holdings Inc

    Apexigen Inc

    APIM Therapeutics AS

    Apollomics Inc

    AstraZeneca Plc

    Atara Biotherapeutics Inc

    BeiGene Ltd

    BioAtla Inc

    BioMed Valley Discoveries Inc

    Calithera Biosciences Inc

    Cebiotex SL

    Clovis Oncology Inc

    CStone Pharmaceuticals Co Ltd

    Eli Lilly and Co

    ENB Therapeutics LLC

    EUSA Pharma (UK) Ltd

    Exelixis Inc

    F. Hoffmann-La Roche Ltd

    Immix BioPharma Inc

    Immodulon Therapeutics Ltd

    Incyte Corp

    Karyopharm Therapeutics Inc

    Kuur Therapeutics Ltd

    Merck & Co Inc

    Merck KGaA

    Ono Pharmaceutical Co Ltd

    Pfizer Inc

    Pharma Mar SA

    Philogen SpA

    PTC Therapeutics Inc

    Shanghai De Novo Pharmatech Co Ltd

    Shanghai Junshi Bioscience Co Ltd

    Tactical Therapeutics Inc

    Tempest Therapeutics Inc

    Tessa Therapeutics Ltd

    Viracta Therapeutics Inc

    Y-mAbs Therapeutics Inc

    Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leiomyosarcoma – Overview

Leiomyosarcoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Leiomyosarcoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leiomyosarcoma – Companies Involved in Therapeutics Development

Leiomyosarcoma – Drug Profiles

Leiomyosarcoma – Dormant Projects

Leiomyosarcoma – Discontinued Products

Leiomyosarcoma – Product Development Milestones

Featured News & Press Releases

Nov 18, 2020: PTC Therapeutics announces key regulatory designations for PTC596 to advance treatment of two rare oncology indications

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Leiomyosarcoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Leiomyosarcoma – Pipeline by 3SBio Inc, 2022

Leiomyosarcoma – Pipeline by Actuate Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Advenchen Laboratories LLC, 2022

Leiomyosarcoma – Pipeline by Agenus Inc, 2022

Leiomyosarcoma – Pipeline by Alphamab Oncology, 2022

Leiomyosarcoma – Pipeline by ALX Oncology Holdings Inc, 2022

Leiomyosarcoma – Pipeline by Apexigen Inc, 2022

Leiomyosarcoma – Pipeline by APIM Therapeutics AS, 2022

Leiomyosarcoma – Pipeline by Apollomics Inc, 2022

Leiomyosarcoma – Pipeline by AstraZeneca Plc, 2022

Leiomyosarcoma – Pipeline by Atara Biotherapeutics Inc, 2022

Leiomyosarcoma – Pipeline by BeiGene Ltd, 2022

Leiomyosarcoma – Pipeline by BioAtla Inc, 2022

Leiomyosarcoma – Pipeline by BioMed Valley Discoveries Inc, 2022

Leiomyosarcoma – Pipeline by Calithera Biosciences Inc, 2022

Leiomyosarcoma – Pipeline by Cebiotex SL, 2022

Leiomyosarcoma – Pipeline by Clovis Oncology Inc, 2022

Leiomyosarcoma – Pipeline by CStone Pharmaceuticals Co Ltd, 2022

Leiomyosarcoma – Pipeline by Eli Lilly and Co, 2022

Leiomyosarcoma – Pipeline by ENB Therapeutics LLC, 2022

Leiomyosarcoma – Pipeline by EUSA Pharma (UK) Ltd, 2022

Leiomyosarcoma – Pipeline by Exelixis Inc, 2022

Leiomyosarcoma – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Leiomyosarcoma – Pipeline by Immix BioPharma Inc, 2022

Leiomyosarcoma – Pipeline by Immodulon Therapeutics Ltd, 2022

Leiomyosarcoma – Pipeline by Incyte Corp, 2022

Leiomyosarcoma – Pipeline by Karyopharm Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Kuur Therapeutics Ltd, 2022

Leiomyosarcoma – Pipeline by Merck & Co Inc, 2022

Leiomyosarcoma – Pipeline by Merck KGaA, 2022

Leiomyosarcoma – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Leiomyosarcoma – Pipeline by Pfizer Inc, 2022

Leiomyosarcoma – Pipeline by Pharma Mar SA, 2022

Leiomyosarcoma – Pipeline by Philogen SpA, 2022

Leiomyosarcoma – Pipeline by PTC Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022

Leiomyosarcoma – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Leiomyosarcoma – Pipeline by Tactical Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Tempest Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Tessa Therapeutics Ltd, 2022

Leiomyosarcoma – Pipeline by Viracta Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Y-mAbs Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Yooyoung Pharm Co Ltd, 2022

Leiomyosarcoma – Dormant Projects, 2022

Leiomyosarcoma – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Leiomyosarcoma, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.